RxDoctor Payments Data

Elizabeth Smith Tryon, MD

Internal Medicine · Lake Havasu City, AZNPI 1700864436

Payments from drug & device makers

$4,446in general payments, 2019–2025

Across 272 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$941
  • Novo Nordisk$798
  • Pfizer$700
  • Amgen$324
  • Astellas Pharma US Inc$311
  • AbbVie$237
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,446100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,446 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$363,656
Medicare patients
707
Services billed
11,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$89,756
TrulicityDulaglutide32$69,188
XareltoRivaroxaban53$66,345
EliquisApixaban40$63,901
FarxigaDapagliflozin Propanediol26$33,199
MounjaroTirzepatide24$32,503
JardianceEmpagliflozin22$27,439
Breo ElliptaFluticasone/Vilanterol15$16,154
MyrbetriqMirabegron12$15,508
Tresiba Flextouch U-100Insulin Degludec24$9,785
Testosterone25$8,935
BelsomraSuvorexant14$7,936
Levothyroxine Sodium804$6,695
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$5,171
Rosuvastatin Calcium350$5,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$219$101,69156 claims
Novo NordiskOzempic, Novolog$798$93,16087 claims
Johnson & JohnsonXarelto$941$66,34553 claims
PfizerEliquis$700$63,90140 claims
Boehringer IngelheimJardiance$96$27,43922 claims
GSKBreo Ellipta$107$16,15415 claims
Astellas Pharma US IncMyrbetriq$311$15,50812 claims
MerckBelsomra$67$7,93614 claims
Sanofi-aventis U.S. LLCLantus$56$4,86519 claims
AbbVieSynthroid$237$4,46178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Lake Havasu City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →